1. Home
  2. MSN vs GTBP Comparison

MSN vs GTBP Comparison

Compare MSN & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Emerson Radio Corporation

MSN

Emerson Radio Corporation

HOLD

Current Price

$0.38

Market Cap

8.4M

ML Signal

HOLD

Logo GT Biopharma Inc.

GTBP

GT Biopharma Inc.

HOLD

Current Price

$0.50

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSN
GTBP
Founded
1948
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
8.8M
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
MSN
GTBP
Price
$0.38
$0.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
112.6K
1.5M
Earning Date
02-17-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.75
EPS
N/A
N/A
Revenue
$77,829,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$0.26
52 Week High
$0.85
$3.73

Technical Indicators

Market Signals
Indicator
MSN
GTBP
Relative Strength Index (RSI) 41.08 60.81
Support Level $0.36 $0.40
Resistance Level $0.41 $0.59
Average True Range (ATR) 0.03 0.04
MACD -0.00 0.00
Stochastic Oscillator 23.80 94.36

Price Performance

Historical Comparison
MSN
GTBP

About MSN Emerson Radio Corporation

Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.

Share on Social Networks: